1. Short-term results of intrathecal injection of low-dose bupivacaine in outpatients with chronic low back and lower extremity pain
- Author
-
Kaoru Fujii, Junko Shimao, Norihito Hayashi, Akifumi Kanai, Yuki Nagahara, and Takashi Okamoto
- Subjects
Adult ,Male ,medicine.medical_specialty ,Intrathecal ,03 medical and health sciences ,0302 clinical medicine ,Lumbar ,Double-Blind Method ,Informed consent ,Humans ,Medicine ,Orthopedics and Sports Medicine ,Anesthetics, Local ,Adverse effect ,Injections, Spinal ,Aged ,Pain Measurement ,Aged, 80 and over ,Bupivacaine ,030222 orthopedics ,Dose-Response Relationship, Drug ,business.industry ,Chronic pain ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Low back pain ,Lower Extremity ,Anesthesia ,Female ,Surgery ,Neurosurgery ,Chronic Pain ,medicine.symptom ,business ,Low Back Pain ,030217 neurology & neurosurgery ,medicine.drug - Abstract
To investigate the safety and efficacy of intrathecal injection as an alternative to epidural injection for analgesia. Seventy consecutive outpatients with chronic low back and lower extremity pain received lumbar intrathecal injection of low-dose isobaric bupivacaine using a 25-gauge pencil-point needle. The patients received 0.5, 1.0, and 1.5 mg of bupivacaine at 1-week intervals to determine the optimal dose. Thereafter, they received two more weekly injections with the optimal dose. The safety and efficacy of the treatment were assessed over a 1-year period. No serious adverse events were encountered. The optimal dose of bupivacaine (1.0 mg in 60% of patients) alleviated pain and disability (both, p
- Published
- 2018